Abstract
An investigational antiviral treatment may significantly reduce the risk of hospitalisation or death in at-risk non-hospitalised patients with COVID-19, according to a statement released by the pharmaceutical company, Merck. In what could become the first oral antiviral treatment for COVID-19, molnupiravir — which is being developed by Merck in collaboration with Ridgeback Biotherapeutics — […]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
